Hologic Inc (HOLX)

Currency in USD
66.89
-0.93(-1.37%)
Closed·
After Hours
66.04-0.85(-1.27%)
·
HOLX Scorecard
Full Analysis
Management has been aggressively buying back shares
HOLX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
66.8669.07
52 wk Range
51.9084.67
Key Statistics
Prev. Close
67.82
Open
69.07
Day's Range
66.86-69.07
52 wk Range
51.9-84.67
Volume
1.68M
Average Volume (3m)
2.93M
1-Year Change
-17.65%
Book Value / Share
21.73
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
HOLX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
72.00
Upside
+7.64%
Members' Sentiments
Bearish
Bullish
ProTips
14 analysts have revised their earnings upwards for the upcoming period

Hologic Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Hologic Inc Company Profile

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen radiology solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. The company was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Hologic Inc SWOT Analysis


Diagnostic Dominance
Hologic's molecular diagnostics segment shows robust 8% growth, highlighting the company's strength in advanced medical technologies and potential for market expansion
Breast Health Hurdles
Explore Hologic's challenges in its traditionally strong breast health sector and the potential impact on overall company performance and market position
Strategic Capital Use
Delve into Hologic's focus on M&A and share buybacks, balancing short-term EPS support with long-term growth investments in a competitive medical technology landscape
Future Outlook
Analysts project price targets ranging from $70 to $89, reflecting mixed views on Hologic's growth prospects amid ongoing tariff challenges and the need for Q4 FY'25 rebound
Read full SWOT analysis

Hologic Inc Earnings Call Summary for Q3/2025

  • Hologic Q3 2025 EPS beats at $1.08 vs $1.05 forecast; revenue hits $1.024B, slightly above expectations
  • Stock dips 1.57% post-earnings despite beat, reflecting cautious investor sentiment amid economic concerns
  • Company projects Q4 revenue of $1.03-1.04B, EPS $1.09-1.12; FY2025 revenue $4.081-4.091B, non-GAAP EPS $4.23-4.26
  • CEO confident in recovery, expects mid-single digit organic growth in FY2026 driven by international expansion
  • Challenges persist in Breast Health revenue and international markets, particularly China and Africa
Last Updated: 30/07/2025, 23:34
Read Full Transcript

Compare HOLX to Peers and Sector

Metrics to compare
HOLX
Peers
Sector
Relationship
P/E Ratio
26.9x−2.3x−0.5x
PEG Ratio
−1.58−0.170.00
Price/Book
3.1x2.2x2.6x
Price / LTM Sales
3.7x3.8x3.3x
Upside (Analyst Target)
4.0%56.4%42.8%
Fair Value Upside
Unlock11.4%6.5%Unlock

Analyst Ratings

6 Buy
13 Hold
0 Sell
Ratings:
19 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 72.00
(+7.64% Upside)

Earnings

Latest Release
Jul 30, 2025
EPS / Forecast
1.08 / 1.05
Revenue / Forecast
1.02B / 1.01B
EPS Revisions
Last 90 days

HOLX Income Statement

People Also Watch

177.49
IQV
-3.50%
25.21
CNC
-2.63%
84.19
QRVO
-0.89%
104.88
TER
-1.92%

FAQ

What Stock Exchange Does Hologic Trade On?

Hologic is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Hologic?

The stock symbol for Hologic is "HOLX."

What Is the Hologic Market Cap?

As of today, Hologic market cap is 14.89B.

What Is Hologic's Earnings Per Share (TTM)?

The Hologic EPS (TTM) is 2.44.

When Is the Next Hologic Earnings Date?

Hologic will release its next earnings report on 02 Nov 2025.

From a Technical Analysis Perspective, Is HOLX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Hologic Stock Split?

Hologic has split 3 times.

How Many Employees Does Hologic Have?

Hologic has 7063 employees.

What is the current trading status of Hologic (HOLX)?

As of 06 Aug 2025, Hologic (HOLX) is trading at a price of 66.89, with a previous close of 67.82. The stock has fluctuated within a day range of 66.86 to 69.07, while its 52-week range spans from 51.90 to 84.67.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.